DongKoo Bio & Pharma Co., Ltd.
Financials
Valuation Metrics
DongKoo Bio & Pharma Co., Ltd.'s Market Cap is ₩918B. At end of 2025 it was ₩1557B. Ranked #1278 of 2,410 in KR market (top 53%), #697 of 1,631 on KOSDAQ (top 43%), #142 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 61%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 91.80B KRW | KR#1,278/2,410 Sec#142/231 |
| Revenue | 241.43B KRW | KR#931/2,410 Sec#52/231 |
| Net Income | 32.88B KRW | KR#534/2,410 Sec#33/231 |
| Total Assets | 318.60B KRW | KR#1,000/2,410 Sec#64/231 |
| Net Assets | 142.58B KRW | KR#1,170/2,410 Sec#86/231 |
| Employees | 418 | KR#583/2,410 Sec#48/231 |
| Value | ||
| P/E | 2.79x | KR#149/2,410 Sec#6/231 |
| P/B | 0.64x | KR#1,099/2,410 Sec#60/231 |
| P/S | 0.38x | KR#780/2,410 Sec#25/231 |
| EV/EBITDA | 574.41x | KR#1,553/2,410 Sec#111/231 |
| FCF Yield | -23.90% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | 23.06% | KR#128/2,410 Sec#11/231 |
| ROA | 10.32% | KR#256/2,410 Sec#19/231 |
| Op. Margin | 0.14% | KR#1,592/2,410 Sec#111/231 |
| Revenue Growth | -0.46% | KR#1,548/2,410 Sec#154/231 |
| Financial Health | ||
| Debt Ratio | 123.46% | KR#1,733/2,410 Sec#193/231 |
| Total Debt | 121.32B KRW | KR#662/2,410 Sec#40/231 |
| FCF | -21.94B KRW | KR#1,904/2,410 Sec#183/231 |
| Cash | 18.37B KRW | KR#1,296/2,410 Sec#99/231 |
| Current Ratio | 0.90x | KR#1,834/2,410 Sec#177/231 |
| Dividend | ||
| Div. Yield | 3.69% | KR#555/2,410 Sec#23/231 |
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -39.94% | KR#1,729/2,410 Sec#142/231 |
| 1M Return | -8.25% | KR#1,182/2,410 Sec#119/231 |
| From 52W High | -48.81% | KR#1,135/2,410 Sec#89/231 |
| 1Y MDD | -48.60% | KR#897/2,410 Sec#71/231 |
| Trading | ||
| Volume | 93,660 shares | KR#1,179/2,410 Sec#119/231 |
| Trading Value | 300.3M KRW | KR#1,425/2,410 Sec#148/231 |
| Foreign Own. | 1.45% | KR#1,837/2,410 Sec#181/231 |
| Per Share | ||
| EPS | 1,155 KRW | KR#664/2,410 Sec#43/231 |
| BPS | 5,009 KRW | KR#1,503/2,410 Sec#108/231 |
Company Info
Established in 1983 for the manufacturing and sale of finished pharmaceuticals, the company was listed on KOSDAQ in 2018 and holds 5 consolidated subsidiaries, including Loftyrock Investment. It operates a four-business unit system: Pharmaceuticals, focusing on manufacturing and selling professional pharmaceuticals and quasi-drugs; Finance; Medical Services; and Pharmaceutical Wholesale and Consulting. The company maintains its #1 position in dermatology prescriptions, possesses differentiated manufacturing technology, and is actively pursuing entry into the cosmeceutical market and overseas expansion.